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Gastroenteropancreatic neuroendocrine tumors 
(GEP-NETs) are a rare and heterogeneous group of 
tumors arising from the cells of diffuse endocrine 
system (DES) scattered through the mucosa of the 
gastrointestinal tract and pancreas. Tumors were his-
torically termed carcinoid-«cancer-like» due to better 
prognosis than adenocarcinoma. Yearly incidence of 
GEP-NETs is estimated to be 1-2 of 100.000 popula-
tion, but according to newer population registries data 
and autopsy reports it has increased by 5-folds, much 
more than incidence of other gastrointestinal malig-
nancies. A special feature of these  neoplasms is amine 
precursor uptake and decarboxylation, leading to pro-
duction of hormones and bioactive amines (tachyki-
nines, bradykinines, etc.), and therefore a potential for 
causing speciﬁ c hypersecretory syndromes (such as 
WDHA, Zollinger-Ellison, carcinoid, hypoglycemic, 
glucagonoma, somatostatinoma etc.). Another charac-
teristic is a potential to arise accompanied by other 
endocrine gland tumors, associated into syndromes 
of multiple endocrine neoplasia type I (MEN I), neu-
roﬁ bromatosis type I (NF I), and von Hippel Lindau 
disease. According to World Health Organization 
(WHO), GEP-NETs are categorized into well-deﬁ ned 
tumors (benign or low grade malignant), well-deﬁ ned 
neuroendocrine carcinoma and poorly differentiated 
neuroendocrine carcinoma. The classiﬁ cation is based 
on proliferative activity measured by Ki67 index, 
number of mitoses, local invasiveness or metastatic 
potential and according to the secretory status of tu-
mors. Newer classiﬁ cation combines WHO and TNM 
classiﬁ cation, and categorizes GEP-NETs into G1 
and G2- well-differentiated; or G3-low differentiated 
tumors where T3 and T4 (>4cm and local invasions) 
deﬁ nes local and N1 (lymphonodes) and M1 (liver) 
metastases. Due to nonspeciﬁ c  symptoms mimicking 
many different diseases, GEP-NETs are unfortunately 
often diagnosed late in the course of disease (with on 
average 5-7 years delay). Most GEP-NETs are actu-
ally nonfunctional, i.e. not associated with recogniz-
able clinical syndromes. Prominent symptoms rising 
suspicion of GEP-NETs are diarrhea and ﬂ ushing, but 
they are most common when tumors metastasize. Di-
agnosis of GEP-NETs is based on clinical syndromes, 
speciﬁ c tumor markers measured in serum or urine 
of patients, and conﬁ rmed by histopathology reports 
and imaging techniques. Chromogranin A (CgA) rep-
resents a general neuroendocrine marker, important 
in not only diagnostic procedures but also in follow-
up of patients.  In patients with carcinoid (serotonin-
producing GEP-NETs), important marker is serum 
serotonin level, or more often measured serotonin 
metabolite 5-hydroxyindolacetic acid, measured in 
24-hour urine output. For the histopathological con-
ﬁ rmation of GEP-NETs positive immunohistochemi-
cal staining for CgA, synaptophisin, neuron-speciﬁ c 
enolase (NSE) are needed. Informative histopatholog-
ical report must also include Ki67 index and number 
of mitoses in tumor tissue. A gold standard in imaging 
procedures is octreoscan, but newer radionuclide im-
aging procedures such as PET combined with tracers 
such as 11C-5-HT or 68Ga-DOTATOC will in future 
develop as most effective methods of imaging detec-
tion. Endoscopic procedures, especially endoscopic 
ultrasound are important due to possibility of tissue 
sampling and cytological/hystological tumor conﬁ r-
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mation. GEP-NETs are potentially curable when sur-
gery is performed in early staged tumors. Surgical 
treatment is also important for abrogation of symp-
toms, even in cases of advanced GEP-NETs. In cases 
of functionally active tumors, causing speciﬁ c, pre-
viously mentioned syndromes, biotherapy in form of 
somatostatin analogues is used but effects produced 
through receptor subtype 2 are thought also to cause 
tumor apoptosis and proliferation inhibition. Soma-
tostatin (111In-DTPA-octreotide, 90Y-DOTA-octreotide 
and 177Lu-DOTA-octreotide) is also used as a basis of 
receptor targeted radionucleotide therapy. Chemother-
apy for treatment of GEP-NETs has a limited effect, 
and is used in advanced tumors, with somewhat better 
response seen in cases of pancreatic neuroendocrine 
tumors (up to 60%). Currently many new agents, espe-
cially that targeting tumor cell proliferation are under 
investigation for treatment of GEP-NETs. Promising 
results come from studies investigating mTOR inhibi-
tors, tirozine kinase inhibitors for different growth 
factors, especially VEGF.
